A randomized, 5-arm dose finding study with a mite allergoid SCIT in allergic rhinoconjunctivitis patients

Area of Science:

• Immunology
• Allergology
• Clinical Pharmacology

Background:

• Previous studies established the safety of mite allergoid subcutaneous allergen immunotherapy (SCIT).
• House dust mite (HDM)-induced allergic rhinoconjunctivitis (ARC) affects a significant patient population.
• Optimizing SCIT dosage is crucial for maximizing therapeutic benefits.

Purpose of the Study:

• To determine the optimal safe and effective dose of mite allergoid SCIT for HDM-induced ARC.
• To evaluate dose-response relationships in patients undergoing SCIT.
• To assess clinical efficacy and immunological markers at various SCIT concentrations.

Main Methods:

• A randomized, placebo-controlled trial involving 290 adult ARC patients.
• Patients received escalating doses of mite allergoid SCIT (6,667 to 100,000 AUeq/ml) or placebo for 12 months.
• The primary endpoint was clinical response assessed by titrated nasal provocation tests (TNPT) after 12 months.

Main Results:

• Statistically significant improvements in TNPT were observed with SCIT concentrations of ≥20,000 AUeq/ml after 12 months.
• No significant differences were noted at the 6-month follow-up.
• Dose-dependent increases in specific serum IgG and IgG4 levels were observed, with more adverse events at the highest dose.

Conclusions:

• Mite allergoid SCIT at concentrations of ≥20,000 AUeq/ml demonstrated clinical efficacy and immunological effects in HDM-induced ARC.
• The risk-benefit ratio supports further clinical development of 20,000 AUeq/ml and 50,000 AUeq/ml strengths.
• SCIT is a viable treatment option for managing HDM allergy.